×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| SUN PHARMA ADVANCED RESEARCH C | 187.8 | -518.7 | 96.4 | -1.6 | 5,384 | |
| Supriya Lifescience Limited | 1477.48 | 347.9 | 1450.74 | 4.32 | 5249 | 29.5 |
| SUVEN LIFE SCIENCES LTD. | 24.56 | -147.79 | 18.67 | -0.68 | 5147 |
Sun Pharma Advanced Research Company Ltd., with Security Code 532872, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 131.1 | 47.7 | 24.0 | 21.2 | 13.9 | 16.6 | 16.8 | 12.9 | 14.9 | 27.2 |
| Expenses | 114.9 | 137.3 | 126.1 | 112.7 | 116.5 | 124.1 | 111.9 | 116.7 | 89.3 | 81.0 |
| Operating Profit | 16.2 | -89.6 | -102.2 | -91.5 | -102.6 | -107.5 | -95.1 | -103.9 | -74.4 | -53.9 |
| OPM % | 12.34% | -187.82% | -426.64% | -431.87% | -740.4% | -649.28% | -565.85% | -807.54% | -498.86% | -198.05% |
| Other Income | 0.0 | 10.7 | 10.2 | 8.5 | 6.4 | 4.4 | 1.6 | 0.0 | 0.2 | 0.0 |
| Interest | 2.9 | 0.2 | 0.3 | 0.3 | 0.3 | 0.9 | 0.5 | 1.1 | 2.8 | 4.5 |
| Depreciation | 3.1 | 2.9 | 3.1 | 3.2 | 3.2 | 2.7 | 2.8 | 2.8 | 2.8 | 2.6 |
| Profit before tax | 10.2 | -82.0 | -95.4 | -86.4 | -99.7 | -106.7 | -96.8 | -107.7 | -79.7 | -60.9 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | 10.2 | -82.0 | -95.4 | -86.4 | -99.7 | -106.7 | -96.8 | -107.7 | -79.7 | -61.0 |
| EPS in Rs | 0.35 | -2.55 | -2.94 | -2.66 | -3.07 | -3.29 | -2.98 | -3.32 | -2.46 | 0 |
| Metrics | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|
| Sales | 21.2 | 13.9 | 16.6 | 16.8 | 12.9 | 14.9 | 27.2 | 9.6 |
| Expenses | 112.7 | 116.5 | 122.4 | 110.2 | 115.8 | 88.6 | 80.3 | 61.7 |
| Operating Profit | -91.5 | -102.6 | -105.8 | -93.4 | -102.9 | -73.7 | -53.1 | -52.1 |
| OPM % | -431.87% | -740.4% | -639.07% | -555.38% | -800.23% | -494.23% | -195.37% | -540.25% |
| Other Income | 8.5 | 6.4 | 4.4 | 1.6 | 0.0 | 0.2 | 0.0 | 9.1 |
| Interest | 0.3 | 0.3 | 0.9 | 0.6 | 1.1 | 2.8 | 4.5 | 6.2 |
| Depreciation | 3.2 | 3.2 | 3.1 | 3.1 | 3.2 | 3.1 | 3.0 | 2.7 |
| Profit before tax | -86.4 | -99.7 | -105.4 | -95.5 | -107.2 | -79.4 | -60.6 | -51.8 |
| Tax % | 0% | 0% | 0.4% | 0.4% | -0.1% | -0.1% | 0% | -0.1% |
| Net Profit | -86.4 | -99.7 | -105.8 | -95.9 | -107.3 | -79.5 | -59.8 | -51.9 |
| EPS in Rs | -2.66 | -3.07 | -3.26 | -2.96 | -3.31 | -2.45 | 0 | -1.6 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -7% |
| 5 Years: | -1% |
| 3 Years: | -19% |
| TTM: | -5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -2% |
| 3 Years: | -30% |
| TTM: | 11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -9% |
| 5 Years: | 5% |
| 3 Years: | -9% |
| 1 Year: | -23% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| TTM: | -5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| TTM: | 12% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -9% |
| 5 Years: | 5% |
| 3 Years: | -9% |
| 1 Year: | -23% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|